Targeting BRAF Class II and III Mutations in NSCLC with the pan-RAF inhibitor Exarafenib Reveals ARAF-KSR1-Mediated Resistance and Rational Combination Strategies.

Saved in:
Bibliographic Details
Title: Targeting BRAF Class II and III Mutations in NSCLC with the pan-RAF inhibitor Exarafenib Reveals ARAF-KSR1-Mediated Resistance and Rational Combination Strategies.
Authors: Manabe T; Department of Medicine, University of California, San Francisco, San Francisco, CA, 94158, USA.; Department of Cellular and Molecular Pharmacology, University of California, San Francisco, San Francisco, CA, 94158, USA.; Helen Diller Family Comprehensive Cancer Center, University of California, San Francisco, San Francisco, CA, 94158, USA., Bergo HC; Department of Medicine, University of California, San Francisco, San Francisco, CA, 94158, USA.; Department of Cellular and Molecular Pharmacology, University of California, San Francisco, San Francisco, CA, 94158, USA.; Helen Diller Family Comprehensive Cancer Center, University of California, San Francisco, San Francisco, CA, 94158, USA., Li Q; Department of Medicine, University of California, San Francisco, San Francisco, CA, 94158, USA.; Department of Cellular and Molecular Pharmacology, University of California, San Francisco, San Francisco, CA, 94158, USA.; Helen Diller Family Comprehensive Cancer Center, University of California, San Francisco, San Francisco, CA, 94158, USA., Wang TS; Kinnate Biopharma, San Diego, CA, 92130, USA., Severson P; Kinnate Biopharma, San Diego, CA, 92130, USA., Miller N; Kinnate Biopharma, San Diego, CA, 92130, USA., Lee C; Kinnate Biopharma, San Diego, CA, 92130, USA., Donderici EY; Guardant Health, Redwood City, CA, 64063, USA., Zhang N; Guardant Health, Redwood City, CA, 64063, USA., Wu W; Department of Medicine, University of California, San Francisco, San Francisco, CA, 94158, USA.; Department of Cellular and Molecular Pharmacology, University of California, San Francisco, San Francisco, CA, 94158, USA.; Helen Diller Family Comprehensive Cancer Center, University of California, San Francisco, San Francisco, CA, 94158, USA., Chou YT; Department of Medicine, University of California, San Francisco, San Francisco, CA, 94158, USA.; Department of Cellular and Molecular Pharmacology, University of California, San Francisco, San Francisco, CA, 94158, USA.; Helen Diller Family Comprehensive Cancer Center, University of California, San Francisco, San Francisco, CA, 94158, USA., Kerr DL; Department of Medicine, University of California, San Francisco, San Francisco, CA, 94158, USA.; Department of Cellular and Molecular Pharmacology, University of California, San Francisco, San Francisco, CA, 94158, USA.; Helen Diller Family Comprehensive Cancer Center, University of California, San Francisco, San Francisco, CA, 94158, USA., Allegakoen P; Department of Medicine, University of California, San Francisco, San Francisco, CA, 94158, USA.; Department of Cellular and Molecular Pharmacology, University of California, San Francisco, San Francisco, CA, 94158, USA.; Helen Diller Family Comprehensive Cancer Center, University of California, San Francisco, San Francisco, CA, 94158, USA., Grandinetti KB; Kinnate Biopharma, San Diego, CA, 92130, USA., Soroceanu L; Kinnate Biopharma, San Diego, CA, 92130, USA., Pelham RJ; Kinnate Biopharma, San Diego, CA, 92130, USA., Martin ES; Kinnate Biopharma, San Diego, CA, 92130, USA., Murphy EA; Kinnate Biopharma, San Diego, CA, 92130, USA., Khanna V; Division of Oncology, Department of Medicine, Stanford University School of Medicine, Stanford, CA, 94305, USA., Neal JW; Division of Oncology, Department of Medicine, Stanford University School of Medicine, Stanford, CA, 94305, USA., Chen CT; Division of Oncology, Department of Medicine, Stanford University School of Medicine, Stanford, CA, 94305, USA., Kato S; Division of Hematology and Oncology, University of California San Diego, Moores Cancer Center, La Jolla, CA, 92093, USA., Williams R; Kinnate Biopharma, San Diego, CA, 92130, USA., Bivona TG; Department of Medicine, University of California, San Francisco, San Francisco, CA, 94158, USA.; Department of Cellular and Molecular Pharmacology, University of California, San Francisco, San Francisco, CA, 94158, USA.; Helen Diller Family Comprehensive Cancer Center, University of California, San Francisco, San Francisco, CA, 94158, USA.; Chan-Zuckerberg Biohub, San Francisco, CA 94158, USA.
Source: Research square [Res Sq] 2025 Oct 09. Date of Electronic Publication: 2025 Oct 09.
Publication Type: Journal Article; Preprint
Journal Info: Country of Publication: United States NLM ID: 101768035 Publication Model: Electronic Cited Medium: Internet ISSN: 2693-5015 (Electronic) Linking ISSN: 26935015 NLM ISO Abbreviation: Res Sq Subsets: PubMed not MEDLINE
Database: MEDLINE Ultimate
Description
ISSN:2693-5015
DOI:10.21203/rs.3.rs-5135027/v1